Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Búsqueda de licenciatario para una nueva clase de antibióticos contra infecciones comunes y graves

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20171228001
Publicado:
10/01/2018
Caducidad:
10/01/2019
Resumen:
Una universidad alemana busca un licenciatario para una nueva clase de antibióticos contra bacterias Gram-positivas que acaba de desarrollar. Las bacterias Gram-positivas se encuentran entre los patógenos más peligrosos para el ser humano. Esta nueva clase de antibiótico puede utilizarse también como probiótico, y sus ventajas incluyen la eliminación rápida de bacterias patógenas, la baja toxicidad y la diana molecular, que puede ser una estructura bioquímica que no es blanco de antibióticos establecidos. La cepa productora de antibiótico se aplica en medicina humana, pero también en medicina veterinaria contra una amplia variedad de bacterias Gram-positivas. La empresa busca compañías farmacéuticas con experiencia en desarrollo de medicamentos comercializables.

Details

Tittle:
Licensing Partner sought for new class of Antibiotics effective against common and severe infections
Summary:
A German University is searching a licensing partner for a newly developed class of Antibiotics against Gram-positive bacteria. Among them are some of the most dangerous pathogens for humans. It can be applied as an antibiotic or as a probiotic. Advantages of this new class are very rapid killing of pathogenic bacteria, low toxicity and an assumed targeting of structures, so far not covered by established antibiotics.
Description:
A German Research Group of a University has identified a new class of Antibiotics, showing extraordinary effects in animal models against highly-resistant bacteria, called Gram-positive Bacteria.
Among Gram-positive bacteria are some of the most dangerous pathogens for humans. Especially Methicillin-resistant Staphylococcus aureus (MRSA) is responsible for a high percentage of hospital-acquired deadly infections, because of its resistance against common Antibiotics. The new found antibiotic class offers the possibility of developing new pharmaceutically applicable antibiotics.
On the other side, the newly identified naturally human-associated bacterial antibiotic producer strain (S. lugdunensis IVK28 wild type) could be applied as a probiotic cure before patients enter hospital. This could avoid costly decolonization of human commensal bacteria before surgery. Also it could replace usual antibiotics and thus reduce the hospitalization duration.
The antibiotic producer strain is applicable in human medicine but also in veterinary medicine against a broad range of Gram-positive bacteria. A patent application covering the chemical structures, the genetic background of the producer strain, the bioactivity of the new substances and their synthesis has been filed.
The University is looking for a licensing partner to take the antibiotic and/or antibiotic producer strain to a new medicine. Ideally this is a pharmaceutical company with experiences in the development of marketable medications.
Advantages and Innovations:
- Very rapid killing of pathogenic bacteria even in the non-growing state. Application of 1 microgram/milliliter (MIC) leads to complete killing of bacteria in vitro.
- Efficiency of the pure compound already shown in a topical mouse model
- Low toxicity: First data point to a low cytotoxic potential against human cells.
- Preliminary data suggest, that molecular target might be a biochemical structure so far not targeted by established antibiotics.
Stage of Development:
Prototype available for demonstration
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Patent application filed, priority date 2015-03-23

Partner sought

Type and Role of Partner Sought:
Type of Partner: Industrial partner
Activity of Partner: Pharmaceutical company
Role of Partner: Licensing of the antibiotic substance for the development of a marketable product.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German
Spanish

Keywords

Technology Keywords:
06001018 Virus, virología / antibióticos / bacteriología